{
  "kind": "treatment",
  "slug": "levomilnacipran-fetzima",
  "type": "antidepressant",
  "name": "Levomilnacipran (Fetzima)",
  "summary": "A serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder in adults.",
  "description": "Levomilnacipran is an SNRI antidepressant structurally related to milnacipran but with a greater potency for norepinephrine reuptake inhibition. It is approved in the United States for the treatment of major depressive disorder (MDD) in adults. Levomilnacipran is taken once daily in an extended-release formulation and is generally well tolerated, with common side effects including nausea, constipation, and hyperhidrosis.",
  "category": "medications/antidepressants",
  "tags": [
    "snri",
    "antidepressant",
    "depression"
  ],
  "metadata": {
    "drug_classes": [
      "SNRI",
      "Antidepressant"
    ],
    "therapeutic_categories": [
      "Depression",
      "Mood Disorders"
    ],
    "mechanism_categories": [
      "SNRI"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Fetzima"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary Care"
    ],
    "fda_approval_year": 2013
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression"
    ],
    "off_label_uses": [
      "Generalized Anxiety Disorder",
      "Fibromyalgia (related drug milnacipran is approved for this use)"
    ],
    "contraindications": [
      "Concurrent use of MAOIs or within 14 days of stopping an MAOI",
      "Known hypersensitivity to levomilnacipran or milnacipran"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Heart rate",
      "Signs of serotonin syndrome"
    ],
    "efficacy_rating": {
      "depression": 4,
      "anxiety": 2,
      "overall_tolerability": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "levomilnacipran",
      "fetzima",
      "snri",
      "antidepressant"
    ],
    "synonyms": [],
    "common_misspellings": [
      "levomilnacipram",
      "levomilnacipan"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major Depressive Disorder (MDD)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Potent inhibition of norepinephrine reuptake and moderate inhibition of serotonin reuptake, increasing synaptic concentrations of both neurotransmitters."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "20 mg once daily for 2 days, then increase to 40 mg once daily",
        "titrate": "Increase by 40 mg/day at intervals of at least 2 days as tolerated",
        "usual_range": "40–120 mg/day",
        "max": "120 mg/day"
      },
      "geriatric": "No specific adjustment, but monitor closely for cardiovascular effects",
      "hepatic_impairment": "Not recommended in severe hepatic impairment",
      "renal_impairment": "Max 80 mg/day if moderate; 40 mg/day if severe"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Extended-release capsules: 20 mg, 40 mg, 80 mg, 120 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Initial improvement may be seen within 1–2 weeks; full antidepressant effect usually takes 4–8 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "constipation",
        "hyperhidrosis",
        "tachycardia",
        "erectile dysfunction",
        "palpitations"
      ],
      "less_common": [
        "urinary hesitation",
        "blurred vision",
        "anxiety",
        "insomnia"
      ],
      "serious": [
        "serotonin syndrome",
        "hypertensive crisis with MAOIs",
        "angle-closure glaucoma"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults.",
      "other": [
        "May increase blood pressure and heart rate; monitor regularly",
        "Risk of serotonin syndrome when combined with other serotonergic agents",
        "Taper gradually to avoid discontinuation symptoms"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Serotonin syndrome",
          "action": "Contraindicated; 14-day washout"
        },
        {
          "with": "Serotonergic drugs",
          "risk": "Serotonin syndrome",
          "action": "Monitor closely"
        },
        {
          "with": "Drugs increasing blood pressure",
          "risk": "Additive hypertension",
          "action": "Monitor BP"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Blood pressure and heart rate at baseline and periodically",
        "Mood and suicidality, especially early in treatment",
        "Signs of serotonin syndrome"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks; limited human data",
      "lactation": "Unknown if excreted in breast milk; use caution",
      "pediatrics": "Safety and efficacy not established",
      "geriatrics": "Monitor cardiovascular parameters closely"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose over at least 1–2 weeks to minimize withdrawal symptoms such as dizziness, irritability, and sensory disturbances."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Greater norepinephrine selectivity may benefit patients with low energy or fatigue",
        "Monitor for urinary retention, especially in men with prostate enlargement",
        "Extended-release formulation allows once-daily dosing"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Fetzima Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "APA Practice Guideline for the Treatment of Patients With Major Depressive Disorder",
          "url": "https://psychiatryonline.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Levomilnacipran (Fetzima): SNRI Antidepressant for MDD",
    "description": "Levomilnacipran (Fetzima) is an SNRI approved for major depressive disorder, with a strong norepinephrine reuptake inhibition profile."
  }
}
